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Abstract: Breast cancer is one of the leading causes of cancer related deaths worldwide. Breast cancer-related
mortality is associated with the development of metastatic potential of primary tumor lesions. The chemokine receptor CXCR4 has been found to be a prognostic marker in various types of cancer, including breast cancer. Recent
advances in the field of cancer biology has pointed to the critical role that CXCR4 receptor and its ligand CXCL12
play in the metastasis of various types of cancer, including breast cancer. Breast tumors preferentially metastasize
to the lung, bones and lymph nodes, all of which represent organs that secrete high levels of CXCL12. CXCL12 acts
as a chemoattractant that drives CXCR4-positive primary tumor cells towards secondary metastatic sites leading to
the onset of metastatic lesions. Since its discovery in 2001, the CXCR4 field has progressed at a very fast rate and
further studies have pointed to the role of CXCR4 in dissemination of tumor cells from primary sites, transendothelial migration of tumor cells as well as the trafficking and homing of cancer stem cells. This review summarizes the
information that has been obtained over the years regarding the role of CXCL12-CXCR4 signaling in breast cancer,
discusses its potential application to the development of new therapeutic tools for breast cancer control, and elucidates the potential therapeutic challenges which lie ahead and the future directions that this field can take for the
improvement of prognosis in breast cancer patients.
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Introduction
Breast cancer is the leading cause of cancerrelated deaths among women. In its early stages, breast cancer is usually not fatal. However,
the development of metastatic spread of the
disease is responsible for at least 90% of the
cancer-associated mortality. The survival rate
falls from 90% for localized breast cancer to
20% for metastatic breast cancer. Despite this
fact, the precise mechanism leading to metastasis remains the most poorly understood component of cancer pathogenesis. The process of
metastasis is known to be the result of several
sequential steps - cancer cells from a primary
tumor locally invade the surrounding tissue by
penetrating the basement membrane (local
invasion), enter the microvasculature of the
lymph and blood systems (intravasation), survive the circulation as circulating tumor cells
(CTCs), exit from the bloodstream (extravasation), survive at distant locations and adapt to

the foreign microenvironment, thereby facilitating cell proliferation and the formation of a
macroscopic secondary tumor. It is the capacity
to metastasize to many anatomical sites that
makes the treatment of breast cancer at its
advanced stage, a supreme challenge till today.
Significantly, certain organs represent common
metastatic destinations (for example, the liver,
lung, lymph nodes and bone marrow), whereas
metastasis to others (including the kidneys,
pancreas and skin) is comparatively rare.
Chemokines are 8 to 12 kDa peptides that
function as chemoattractant cytokines involved
in cell activation, differentiation and trafficking.
Chemokines are known to bind to specific
G-protein coupled receptors. The chemokine
CXCL12 (a.k.a. stromal cell derived factor-1 or
SDF-1) binds to its receptor C-X-C chemokine
receptor type 4 (CXCR4). Like all chemokine
receptors, CXCR4 belongs to the superfamily of
seven transmembrane domain heterotrimeric G
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Figure 1. Role of the CXCR4-CXCL12 interaction in primary breast tumor and metastatic sites. The CXCL12 ligand
secreted by cancer-associated-fibroblasts (CAFs), or myofibroblasts, in the breast carcinoma, binds to the cognate
CXCR4 receptor expressed on the cancer cell surface which causes the activation of downstream intracellular proproliferative pathways, thereby enhancing tumor growth directly. CXCL12 also recruits endothelial progenitor cells
(EPCs) from bone marrow into the carcinoma to enhance angiogenesis and thus promote tumor growth. The CXCL12-CXCR4 binding leads to migration of CXCR4-positive cancer cells away from the primary tumor in response to
a CXCL12 gradient. The CXCL12 ligand acts as a chemoattractant that drives primary tumor cells towards CXCL12rich secondary metastatic sites leading to the onset of metastatic lesions.

protein-coupled receptors (GPCR). The CXCL12CXCR4 signaling pathway has been recognized
to having a very critical role in the retention and
homing of hematopoietic stem cells in the bone
marrow microenvironment and lymphocyte
trafficking. It has also been implicated in the
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maintenance of the secondary lymphoid structure. As shown in Figure 1, CXCL12 has been
found to be expressed constitutively in several
organs including the lungs, liver, bone marrow,
skeletal muscle, kidney, brain, etc. Recent
breakthroughs in cancer biology research and
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Table 1. History of development of research on the involvement of CXCR4 receptor in breast cancer
metastasis
YEAR
1889

INVESTIGATOR
Stephen Paget
[4]

TITLE OF PUBLICATION
The Distribution of Secondary Growths
in Cancer of the Breast

2001

Anja Muller and
Albert Zlotnik
[5]
Schioppa et al.
[7]

Involvement of chemokine receptors in
breast cancer metastasis

2003

2005

Akira Orimo and
Robert Weinberg
[8]

2005

Kucia et al.
[9]

2011

Hiroshi Yagi and
J. Silvio Gutkind
[10]

Regulation of the Chemokine Receptor
CXCR4 by Hypoxia
Stromal Fibroblasts present in invasive
human breast carcinomas promote Tumor Growth and Angiogenesis through
elevated SDF-1/CXCL12 secretion
Trafficking of Normal Stem Cells and
Metastasis of Cancer Stem Cells involve
similar mechanisms : Pivotal Role of
the SDF-1 CXCR4 axis.
A synthetic Biology Approach Reveals a
CXCR4-G13-Rho Signalling Axis Driving
Transendothelial Migration of Metastatic Breast Cancer Cells

development have proved that CXCR4 plays a
pivotal role in breast cancer (and cancer in general), especially in the metastatic spread of the
disease [1-3]. Interestingly, the organs which
exhibit an enhanced secretion of CXCL12 are
also the most common secondary metastatic
sites of breast cancer. This observation has further highlighted the important role played by
the CXCL12-CXCR4 signaling axis in breast cancer metastasis. This review will highlight the
key role of CXCR4 and the regulation of its
expression in breast cancer as well as the
potential of targeting CXCL12-CXCR4 signaling
as a future therapeutic strategy in breast cancer treatment.
Historical review of the research breakthroughs in the field
For a long time it has been recognized that the
capacity of cancer cells to metastasize to many
secondary sites is the key factor that makes
the prognosis of cancer so poor. In case of
breast cancer, it has been seen that a few secondary organs such as the bone marrow, lungs,
liver, lymph nodes and brain are more favorable
as metastatic sites than other organs.
As outlined in Table 1, in 1889, Stephen Paget
attempted to explain this phenomenon through
48

DESCRIPTION
This paper first elucidated the “seed versus
soil” hypothesis in cancer metastasis progression
This paper first pointed out the pivotal role of
the CXCL12-CXCR4 interaction in pregression of
breast cancer metastasis
This study showed that hypoxic conditions
favour the expression of CXCR4 in tumor cells
via activation by HIF1alpha
This study identified that CXCR4-CXCL12 binding recruits EPCs to tumor cells, promoting
angiogenesis and tumor growth
This study first established the role of the
CXCR4 in cancer stem cell trafficking and
metastasis
This paper elucidated the role of CXCR4 in the
initial steps of tumor cell dissemination from
primary site and intravasation via trans-endothelial migration

a ‘seed and soil’ hypothesis, in which he stated
that tumor cells, somehow liberated from the
primary tumour, would seek ‘nurturing’ conditions that resemble their original microenvironment to grow and thereby create secondary
metastatic lesions [4]. His hypothesis was
proved to be accurate more than a century later
in 2001. A breakthrough study published in
Nature, proved that not only can tumor cells
travel around the body, but they do so under
the influence of signals that determine their
migratory behavior [5]. The study identified the
pivotal role played by the CXCL12-CXCR4 signaling axis in metastasis, particularly breast
cancer metastasis to the lung. Muller and his
colleagues reported that CXCR4 receptors are
highly expressed in breast cancers cells, malignant breast tumors and metastasis. The ligand
CXCL12 also exhibits peak expression in common secondary metastatic sites. In breast cancer cells the CXCL12-CXCR4 ligand-receptor
interaction gives rise to actin polymerization
and pseudopodia formation leading to chemotactic migration of the cells ultimately leading
to metastasis of the cancer cells to CXCL12rich environments. Subsequent studies involving animal models have established that interfering with the CXCR4-CXCL12 interaction
significantly impairs breast cancer metastasis.
Am J Cancer Res 2013;3(1):46-57
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Silencing of CXCR4 receptor was also found to
severely block breast cancer metastasis [6].
Since these reports, there have been various
studies on CXCR4 and its role in breast cancer
metastasis.
In 2003, another breakthrough study identified
that the expression of CXCR4 is induced when
tumor cells are cultured under hypoxic condition [7]. In 2005, Dr. Weinberg’s lab showed
that tumor associated macrophages activate a
particular type of carcinoma-associated mesenchymal cell, the myofibroblast, that secretes
CXCL12 [8]. They established that endothelial
progenitor cells (EPCs) also exhibited the
CXCR4 receptor. Thus through this recruitment
of EPCs to the tumor cells via CXCR4-CXCL12
binding, CXCR4 promotes angiogenesis and
tumor growth directly. Interestingly, in 2005
and 2006, various studies were conducted
which established an important link between
CXCR4 expression and cancer stem cells.
Cancer stem cells have been found to express
CXCR4, and the CXCR4-CXCL12 axis also
directs the trafficking of these cancer stem
cells to CXCL12-rich environments like lymph
nodes, lungs, etc [9]. Finally, in 2011, a breakthrough study showed that CXCR4 is not only
associated with the metastatic spread of
breast cancer cells to secondary organs, it also
plays a key role in the initial steps of tumor cell
intravasation and dissemination from the primary tumor site [10].
The CXCL12-CXCR4 signaling pathway
The binding of CXCL12 to CXCR4 results in
divergent downstream signaling pathways that
mediate chemotactic invasion, cell survival and
regulation of gene transcription. CXCR4 is a
G-protein coupled receptor that is associated
with an intracellular heterotrimeric G-protein
linked to the inner surface of the plasma membrane. The receptor has a seven-transmembrane structure with seven helical regions connected by six extramembrane loops. The
G-protein heterotrimer consists of Gα, Gβ and
Gγ subunits, which remain associated to the
guanine nucleotide GDP at the basal state. On
ligand binding, GDP is released and replaced by
GTP which leads to the separation of the G subunits into a Gα monomer and a Gβγ dimer. GTP
is bound to the Gα monomer. The Gα can exist
in four different forms termed as Gαs,Gαi,Gαq
49

and Gα12. It was believed that the CXCR4 receptor is primarily a Gαi-associated GPCR. However,
recent reports have confirmed that CXCR4 may
be associated with any of the other Gα subunits
as well [11]. The four different Gα subunits
each have distinct functions and activate distinct downstream signaling pathways, thereby
relaying the GPCR signal to different routes.
After the relaying of the signal, GTP is rapidly
hydrolyzed to GDP, leading to the reassociation
of the CXCR4 receptor complex. On the other
hand, Gβγ subunits also activate additional
downstream signaling pathways.
The Gαs subunit stimulates adenylyl cyclase to
produce cyclic AMP (cAMP) which activates
Protein kinase A (PKA) which, in turn activates
the transcription factor, Cyclic AMP-responsive
element-binding protein or CREB. CREB translocates to the nucleus and regulates the transcription of several genes implicated in cancer
progression. For example, the expression of
Glutathione S-transferase protein 1 (GSTP1) is
positively regulated by CREB [12]. Higher
expression of GSTP1 is correlated with higher
drug resistance. The Gαi subunit is pertussistoxin sensitive [13]. Both Gαi and Gαq can activate phospholipase C leading to the production
of secondary messengers diacylglycerol (DAG)
and inositol triphosphate (IP3) which opens up
intracellular calcium stores, thereby facilitating
cellular chemotaxis. DAG, in turn, activates the
protein kinase C family of enzymes [14]. PKCα
is especially involved in regulating tumor cell
migration [15, 16]. PKCα also activates Iκβ
kinase to phosphorylate Iκβ which leads to the
NFκB-mediated regulation of cancer-related
genes. Chemotaxis has also been shown to be
mediated by the activation of MAPK pathways
through the signal relayed by both Gαi and Gαq
subunit. Lastly, the Gα12 subunit activates guanine nucleotide exchange factors (GEF) for the
Rho family of GTPases. A major downstream
target of Rho is the Rho-dependent coiled-coil
kinase (ROCK) which activates non-muscle
myosin II, thereby stimulating migratory activity
in tumor cells [17]. In parallel, CXCR4-mediated
chemotaxis is largely mediated by PI3K which
may be activated by both the Gβγ dimer or Gα
monomer. PI3K activation results in the phosphorylation of several focal adhesion components like FAK which activates downstream signaling pathways which induce migratory activity
in tumor cells.
Am J Cancer Res 2013;3(1):46-57
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Figure 2. Regulation of CXCR4 expression in breast cancer. Proteins or pathways regulating CXCR4 expression at the
transcriptional or post-translational levels are illustrated.

Phosphorylation of the CXCR4 receptor plays a
major role in both positive and negative modulation of CXCR4 downstream signaling [18].
Importantly, phosphorylation induced by ligand
binding can promote receptor desensitization.
Agonist-promoted desensitization is primarily
mediated by members of the GPCR kinase
(GRK) family which specifically phosphorylate
ligand occupied GPCRs [19]. GPCR phosphorylation can promote Gα protein independent
downstream signaling, and may also facilitate
recruitment of arrestins which target the receptors for clathrin-mediated endocytosis [20].
CXCL12 binding promotes the phosphorylation
of seven specific serine residues in the
C-terminal tail by GRK2, GRK3 and GRK6 [18].
GRK3- and GRK6- mediated phosphorylation
results in the activation of downstream
ERK1/2, while calcium mobilization and ERK
activation is negatively modulated by GRK250

mediated CXCR4 phosphorylation. Thus, the
serine-threonine rich cytoplasmic tail of CXCR4
plays a major role in mediating G protein-independent pathways downstream of the receptor.
Furthermore, studies indicate that because of
its recently identified role in the activation of G
proteins on CXCL12 binding, the cytoplasmic
tail may be an essential player in activating G
protein-dependent pathways as well [21].
Regulation of CXCR4 expression
CXCR4 expression has been found to be upregulated in primary tumor cells as well as metastatic lesions. The increased levels of CXCR4
expression have prognostic significance suggesting that the acquisition of the novel cancerpromoting effect is, at least in part, due to
increased receptor numbers and increased
receptor signals. Thus, it is essential to identify
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the mechanism that triggers the upregulation
of CXCR4 receptor in cancer cells leading to
chemotactic migration and ultimately, metastatic spread of the disease.
As outlined in Figure 2, specific mechanisms
have been identified that regulate CXCR4
expression at transcriptional or post-translational level. A detailed analysis of the promoter
region of CXCR4 revealed that it contains a
number of predicted consensus sequences.
The CXCR4 promoter contains a nuclear receptor-1 (NRF-1) binding site [22]. In human rhabdomyosarcomas, NRF-1 was found to upregulate CXCR4 expression [23]. A negative
regulatory element was also identified on the
CXCR4 promoter, located at about -300bp
upstream of the transcriptional start site [22].
Subsequently in 2005 it was proved that Ying
Yang-1 (YY-1) downregulates CXCR4 expression
via the identified negative regulatory element
on the CXCR4 promoter [24]. This study also
demonstrated that the C-terminal Src kinase
negatively regulates CXCR4 transcription by
reducing the YY1-c-myc association in breast
cancer cells.
TGFβ1 upregulates CXCR4 expression in breast
cancer cells (MCF-7) at both mRNA and protein
level [25]. TGFβ1 is known to play a prominent
role in metastasis by enhancing angiogenesis
and suppressing immune surveillance at secondary metastatic sites. More research is
required to investigate whether TGFβ1 regulates the suppression of immune surveillance
via a CXCR4-dependent mechanism during
metastatic colonization of cancer cells.
Activation of EGFR by EGF under hypoxic conditions was found to cause a dramatic upregulation of CXCR4 expression in non-small cell lung
cancer (NSCLC) [26]. Further investigation
revealed that the presence of EGF and a low
oxygen environment lead to the upregulation of
HIF1α expression and subsequently HIF1αdependent CXCR4 gene transcription. In fact, a
constitutively active variant of EGFR, EGFRvIII
has been associated with the regulation of
CXCR4 expression [27]. EGFRvIII regulates
CXCR4 transcription in a hormone-dependent
manner by upregulating the CXCR4 transcription regulator HIF1α in breast cancer cells.
EGFRvIII has also been shown to inhibit AIP4
and β-arrestin1/2 which are involved in CXCR4
receptor internalization and degradation [28,
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29]. Therefore, these studies illustrate two possible mechanisms by which EGFRvIII upregulates CXCR4 expression in breast cancer cells.
The promoter of CXCR4 contains several binding sites for NF-kB and it has recently been
shown that CXCR4 expression in MDA-MB231
breast carcinoma cells is directly regulated by
NF-kB at the transcriptional level [30].
Interestingly, NF-kB is known to be activated in
response to hypoxic stress which itself is a factor responsible for the upregulation of CXCR4
expression in breast carcinoma.
The role of the CXCL12-CXCR4 signaling arc in
promoting angiogenesis has been of supreme
interest to researchers over the years. In 2002,
a study indicated that the Vascular endothelial
growth factor (VEGF) receptor neuropilin-1
mediated VEGF autocrine pathway induced
CXCR4 receptor expression in breast cancer
cells, thereby promoting invasion and migration
of breast cancer cells towards a gradient of the
CXCL12 chemoattractant [31]. Additionally,
blocking the neuropilin-2 receptor with neuropilin2-specific antibodies inhibited the expression of CXCR4 and also significantly decreased
CXCR4-dependent migration of MDA-MB-231
cells towards the CXCL12 ligand [32]. On the
other hand, CXCR4 itself was shown to regulate
VEGF promoter activity in MDA-MB-231 cells
and blocking the CXCR4-CXCL12 interaction
severely impaired VEGF expression levels both
at the mRNA and protein level [33]. Expression
level of VEGF was found to be reduced by 42%
on administering a peptide inhibitor of CXCR4,
CTCE-9908 to a transgenic breast cancer
mouse model [34]. Collectively, these results
indicate that VEGF can enhance CXCR4 expression in breast carcinoma cells via an autocrine
pathway, which in turn can enhance the promoter activity of VEGF itself, suggesting that
VEGF is produced in a feed-forward mechanism
via CXCR4 expression, thus driving enhanced
angiogenesis and increased invasion and
migration in breast tumor cells.
In 2009, Vesnarinone was recognized as a chemotherapeutic agent that downregulated
CXCR4 expression both at the mRNA and protein level [35]. Krüppel-like factor 2 (KLF2) was
identified to be a Vesnarinone-responsive protein that binds to the CXCR4 promoter and
repressed CXCR4 transcription. Zerumbone, a
natural component of subtropical ginger
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(Zingiber zerumbate) was also identified as a
negative regulator of CXCR4 transcription in
Her2-overexpressing breast cancer cells [36].
Recent reports have shown that enhanced
CXCR4 expression in breast cancer cells is also
significantly mediated by post-transcriptional
and post-translational modification of the
receptor. The estrogen receptor has been
shown to play a major role in positively regulating CXCR4 expression by inducing posttranscriptional modification of the receptor, apart
from directly inducing CXCR4 transcription in
breast cancer cells [37]. Hepatocyte growth
factor (HGF) induces functional CXCR4 expression in breast cancer cells through PKCζ and
downstream Rac1 activation. HGF treatment
induces CXCR4 receptor phosphorylation and
can contribute to reduced CXCR4 endocytosis,
thereby facilitating chemotactic migration of
breast tumor cells [38]. Wild-type p53 has been
shown to repress CXCR4 expression, while the
cancer-specific isoform of p53, Δ133p53 failed
to repress CXCR4 promoter activity [39]. This
suggests an alternate mechanism for enhanced
CXCR4 in breast cancer through the expression
of mutated p53 or isoform expression in breast
cancer cells. Furthermore, it has recently been
demonstrated that CXCR4 gene expression in
primary breast tumors is also regulated by DNA
methylation. Loss of DNA methylation in the
CXCR4 promoter is associated with aggressive
tumor growth, invasion and metastasis in
breast cancer patients [40].
Upregulation of CXCR4 under hypoxic conditions
Following the observations made by Muller et
al, in 2001 which identified the critical role of
CXCR4 in breast cancer metastasis, Schioppa
et al, made the important observation that the
expression of CXCR4 is upregulated in tumor
cells resulting from a change in the tumor
micrenvironment. The tumor cells , when cultured in hypoxic conditions, for example,
showed significant overexpression of CXCR4.
Furthermore, CXCR4 has been shown to be
upregulated by hypoxia-induced factor 1 alpha
(HIF-1α)by the same group. This was a very
important development in this field since hypoxic conditions are known to promote cancer
metastasis. Hypoxia develops when the primary tumor attains a certain volume, whereby it
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does not have enough blood supply to nourish
it due to insufficient angiogenesis [41]. Each
tissue has an organized structure, a vascular
supply and a variety of nutrients. When cancer
cells circumvent this normal organisation they
are subject to environmental stress. Such environmental pressures like hypoxia, can select
the tumor cells with the capability to grow in
spite of such environmental challenges and
can also cause them to acquire an aggressive
phenotype. Recent studies on the link between
hypoxia and CXCR4 expression in breast cancer
have provided sufficient evidence that hypoxic
condition selects the tumor cells which go on to
proliferate and metastasize by activating the
expression of CXCR4 in these cells [42]. For
example, in non-small cell lung cancer (NSCLC)
low oxygen tension lead to enhanced CXCR4
expression via a phosphatidyl-inositol 3 –
kinase/PTEN/AKT/mammalian
target
of
rapamycin signal transduction pathway which
leads to the activation of HIF-1α and finally to
HIF1α-dependent transcription of the CXCR4
gene [26]. The CXCR4 promoter contains a consensus HIF1α binding site which when mutated, leads to inhibited CXCR4 gene expression in
the presence of HIF1α. This data suggests that
the HIF1α transcription factor regulates the
expression of CXCR4. A recent study has also
revealed that hypoxia (via HIF-1α) and TGF-β
signaling promote bone metastasis of breast
cancer cells via a synergistic mechanism [43]
Furthermore, under normoxic conditions, the
von Hippel-Lindau tumor suppressor protein
pVHL, negatively regulates CXCR4 expression
because of its ability to target the HIF1α for
degradation. However, under hypoxic conditions, the aforementioned process is suppressed, leading to a significant increase in
HIF1α-dependent CXCR4 expression in breast
carcinoma cells [44]. This suggests a possible
mechanism by which cells of a growing tumor
are reprogrammed to express the CXCR4 receptor, thereby enhancing the metastatic potential
of the tumor cells.
CXCR4 and cancer stem cells
Cancer stem cells are a subpopulation of cells
in the tumor that act as tumor propagating
cells. Cancer stem cells present a challenge to
cancer therapeutics, especially since these
cells can resist DNA damage and are, therefore, unresponsive to chemotherapeutic treat-
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ment and apoptotic drugs. Cancer stem cells
need specific microenvironments to grow and
contribute to the growth of both primary and
secondary metastatic tumors [45]. Various
studies done on brain, prostate as well as
breast tumors have underlined the importance
of quiescent cancer stem cells in the development of cancer [46, 47]. The CXCL12-CXCR4
signaling axis is known to be involved in normal
stem cell homing [48]. Interestingly, cancer
stem cells have also been found to express the
CXCR4 receptor which suggests that the
CXCL12-CXCR4 signaling axis may direct the
trafficking of cancer stem cells to secondary
organs that express high levels of CXCL12
ligand like lungs, lymph nodes, etc [9] It has
been shown in animal models that bone-marrow derived progenitor cells home to specific
distant organs and “niche” sites before the formation of metastasis [49]. The ability of cancer
stem cells to migrate to distant “niche” sites
like the bone marrow-derived progenitor cells
and avoid destruction may explain the reason
for which in many cases, relapse occurs even
after micrometastasis remains dormant for
several years after removal of the primary
tumor. Due to cancer stem cell mediated micrometastasis, relapse can occur several years
after successfully treating the primary tumor.
Interestingly, reports suggest that hypoxia promotes the self-renewal capacity of CD133 positive human glial-derived cancer stem cells [50]
which leads to the expansion of cells bearing
the CXCR4 surface marker. Furthermore, overexpression of NANOG (known to promote cancer stem cell characteristics in tumor cells) in
breast (MCF-7) cancer cells leads to significant
molecular changes, including the upregulation
of the CXCR4 receptor in these cells, accompanied by a significant increase in drug resistance
in MCF-7 cells [51]. In pancreatic cancer, two
populations of cancer stem cells have been
identified: CD133+ cells that maintain primary
tumor growth and migratory CD133+/CXCR4+
cells at the invasive edge of the tumor that promote metastatic growth. Further research may
be done to identify whether breast cancer stem
cells are present in similar subpopulations in
the primary tumor to promote growth and metastatic progression. A recent study has shown
that the CXCR4 receptor maintains a cancer
progenitor population in tamoxifen-resistant
breast cancer cells through aryl hydrocarbon
receptor (AhR) signaling [52].
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Overall, these studies emphasize the role of
CXCR4 in the promotion of malignant cancerous metastatic lesions and highlight the importance of therapeutic intervention to prevent
CXCR4 activation.
Role of CXCR4 in initial cancer cell dissemination from primary tumor site
Ever since the role of CXCR4 in breast cancer
metastasis was first documented in 2001 [5],
this field has moved forward significantly. Many
studies have been conducted which confirms
conclusively that increased abundance of
CXCR4 in breast cancer cells is associated with
enhanced metastatic potential. However,
whether CXCR4 is required for the initial steps
of tumor cell dissemination from the primary
site and intravasation had been largely overlooked. In 2011, Yagi et al reported that CXCR4
is required for the migration of breast cancer
cells from the primary site through the basement membrane. It is also implicated in transendothelial migration via the activation of the
small GTPase Rho, through the heterotrimeric
G-proteins associated with it. CXCL12 acts
through CXCR4 to stimulate migration and
intravasation of the breast cancer cells.
Interestingly, recent reports suggest that
hypoxic conditions induce tumor cell CXCR4
expression along with endothelial CXCL12
expression and stimulate transendothelial
migration towards a CXCL12 gradient thereby
facilitating the initial steps of metastasis [53].
These studies further highlight the critical role
played by CXCR4 receptor in the overall progression and metastasis of breast cancer.
Therapeutic implications
All the work highlighted above point to the
immediate need to disrupt the enhanced
CXCL12-CXCR4 signaling in cancer cells leading to chemotactic migration and metastasis.
In fact, some of the established anti-tumor
treatments like DNA damage based chemotherapy promote hypoxic environment, which
leads to the upregulation of CXCR4 expression,
thereby promoting survival and metastatic
invasion of the tumor. The implication of this
observation is that certain anti-cancer therapy,
while removing the primary tumor, can actually
augment the metastatic potential of the surviving tumor cells by further upregulating the
expression of CXCR4. This increase in CXCR4
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expression may be the cause behind the
decrease in overall patient prognosis. Hence,
the disruption of CXCR4 or preventing the
upregulation of CXCR4 in cancer cells is imperative for effective treatment.
The best studied among the compounds that
inhibit CXCR4-CXCL12 interaction is a CXCR4
antagonist AMD3100. Commonly known as
Plerixafor, AMD3100 has already been shown
to decrease metastatic potential in animal
models [54]. The efficacy of AMD3100 and
other CXCR4 antagonists and inhibitors in preventing cancer is being clinically tested
(ClinicalTrials. Gov identifier: NCT01120457).
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